We have cloned and sequenced the complete genome of a strain of poliovirus type 3 (23127) isolated during an outbreak of poliomyelitis in Finland. The genome is 7435 nucleotides long excluding the 3′ poly(A) stretch and is 95.5% homologous at the amino acid level to the previously sequenced type 3 strain, P3/Leon/37. The most striking feature of the presented sequence is the extent of amino acid substitutions relative to P3/Leon/37 and other type 3 strains in areas of known antigenic importance. The major antigenic determinant for virus neutralization (site 1), located at residues 89 to 100 of VP1, has three amino acid substitutions and there are six substitutions in site 3, a composite site made up of sequences from VP1 and VP3. The variation in these regions probably accounts for the observed unusual antigenicity and may explain why the virus was able to spread in a well-vaccinated community. Sequence comparisons imply that the virus is not derived from the currently used live attenuated vaccine.
CannA. J.,
StanwayG.,
HauptmannR.,
MinorP. D.,
SchildG. C.,
ClarkeL. D.,
MountfordR. C.,
AlmondJ. W.1983; Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins. Nucleic Acids Research 11:1267–1281
EvansD. M. A.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1983; Critical role of an eight amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature, London 304:459–462
FergusonM.,
EvansD. M. A.,
MagrathD. I.,
MinorP. D.,
AlmondJ. W.,
SchildG. C.1985; Induction of broadly reactive, type specific neutralizing antibody to poliovirus type 3 by synthetic peptides. Virology 143:505–515
KewO. M.,
NottayB. K.1985; Evolution of the oral polio vaccine strains in humans occurs by both mutation and intermolecular recombination. In Modern Approaches to Vaccines: Molecular and Chemical Basis of Virus Virulence and Immunogenicity pp 357–362 Edited by
ChanockR. M.,
LemerR. A.
New York: Cold Spring Harbor Laboratory;
KitamuraN.,
SemlerB.,
RothbergP. G.,
LarsenG. R.,
AdlerC. J.,
DornerA. J.,
EminiE. A.,
HanecakR.,
LeeI. J.,
Van Der WerfS.,
AndersonC. W.,
WimmerE.1981; Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature, London 291:547–553
MagrathD. I.,
EvansD. M. A.,
FergusonM.,
SchildG. C.,
MinorP. D.,
HoraudF.,
CrainicR.,
StenvikM.,
HoviT.1986; Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. Journal of General Virology 67:899–905
MinorP. D.,
FergusonM.,
EvansD. M. A.,
AlmondJ. W.,
IcenogleJ. P.1986b; Antigenic structure of polioviruses of serotypes 1, 2 and 3. Journal of General Virology 67:1283–1291
StanwayG.,
CannA. J.,
HauptmannR.,
HughesP.,
ClarkeL. D.,
MountfordR. C.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1983; The nucleotide sequence of poliovirus type 3 Leon 12a1, b: comparison with poliovirus type 1. Nucleic Acids Research 11:5629–5643
StanwayG.,
MountfordR. C.,
CoxS. D. J.,
SchildG. C.,
MinorP. D.,
AlmondJ. W.1984a; Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA : RNA hybrid method. Archives of Virology 81:67–78
StanwayG.,
HughesP. J.,
MountfordR. C.,
ReeveP.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1984b; Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1 b. Proceedings of the National Academy of Sciences, U.S.A. 81:1539–1543
StanwayG.,
HughesP. J.,
MountfordR. C.,
MinorP. D.,
AlmondJ. W.1984c; The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Research 12:7859–7875
ToyodaH.,
KoharaM.,
KataokaY.,
SuganumaT.,
OmataT.,
ImuraN.,
NomotoA.1984; Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. Journal of Molecular Biology 174:561–585